Company news

Fulcrum Therapeutics, Inc. news in 2024

Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Fulcrum Therapeutics to Participate in Upcoming December Conferences

November 25, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

November 12, 2024

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

November 11, 2024

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8: 00 a.m. ET

November 5, 2024

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

September 11, 2024

Fulcrum Therapeutics to Participate in Upcoming September Conferences

August 26, 2024

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

August 18, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

July 30, 2024

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8: 00 a.m. ET

July 23, 2024

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

June 11, 2024

Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

June 5, 2024

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

May 12, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

May 12, 2024

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

May 7, 2024

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8: 00 a.m. ET

May 5, 2024

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

March 27, 2024

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

March 17, 2024

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

March 4, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

February 26, 2024

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8: 00 a.m. ET

February 19, 2024

Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Calls in 2024

Decks in 2024